The percentage of patients who developed new positive anti-double-stranded DNA antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% of placebo-treated patients) and by Crithidia luciliae assay (3% of patients treated with Enbrel compared to none of placebo-treated patients).
A kettősszálú DNS- elleni antitest titer pozitívvá válását Crithidia luciliae assay- ben is gyakrabban észlelték az Enbrel- lel kezelt csoportban (3%), mint a placebo csoportban (0%).